tbuckley/cabot-search huggingface dataset:
Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era
Authors: Jiajun Wang, Xiujing Dou, Jing Song, Yinfeng Lyu, Xin Zhu, Lin Xu, Weizhong Li, Anshan Shan
Journal: Medicinal Research Reviews (2018)

Abstract Antimicrobial peptides (AMPs), critical components of the innate immune system, are widely distributed throughout the animal and plant kingdoms. They can protect against a broad array of infection‐causing agents, such as bacteria, fungi, parasites, viruses, and tumor cells, and also exhibit immunomodulatory activity. AMPs exert antimicrobial activities primarily through mechanisms involving membrane disruption, so they have a lower likelihood of inducing drug resistance. Extensive studies on the structure‐activity relationship have revealed that net charge, hydrophobicity, and amphipathicity are the most important physicochemical and structural determinants endowing AMPs with antimicrobial potency and cell selectivity. This review summarizes the recent advances in AMPs development with respect to characteristics, structure‐activity relationships, functions, antimicrobial mechanisms, expression regulation, and applications in food, medicine, and animals.
P2.01-45 Mutational and Inflammatory Biomarkers for Lung Cancer Patients with Pleural Effusions
Authors: B. Hegedus, D. Valdivia, H. Koziej, E. Loscha, P. Stockhammer, T. Plönes, K. Mardanzai, M. Zaatar, D. Theegarten, C. Aigner
Journal: Journal of Thoracic Oncology (2018)
P3.01-91 Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape
Authors: V. Vaghani, S. Chandwani, M. Hirschmann, S. Dibaj, L.L. Landry, E. Roarty, J. Zhang, W. Rinsurnogkawong, J. Lewis, J. Lee, J.A. Jack A. Roth, S. Swisher, J. Heymach, T. Burke, G. Simon
Journal: Journal of Thoracic Oncology (2018)
Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
Authors: S. Qin, R.S. Finn, M. Kudo, T. Meyer, A. Vogel, M.P. Ducreux, T.M. Macarulla, G. Tomasello, F. Boisserie, J. Hou, C. Li, J. Song, A.X. Zhu
Journal: Annals of Oncology (2018)
OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037
Authors: L. Villaruz, B. Schneider, T. Bauer, A. Spira, G. D'Amato, J. Wasser, A. Balmanoukian, P. Lara, A. Olszanski, T. Gajewski, S. Patel, A. Tarhini, J. Bauml, E. Schmidt, J. Bowman, J. Daniel, S. Owens, T. Mitchell
Journal: Journal of Thoracic Oncology (2018)
P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 &lt;50%
Authors: N. Rizvi, S. Lee, P. Curtis, W. Caldwell, B. Gao, P. Rietschel
Journal: Journal of Thoracic Oncology (2018)
MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
Authors: T. Mok, K. Nakagawa, R. Rosell, K. Lee, J. Corral, M.R. Migliorino, A. Pluzanski, R. Linke, G. Devgan, E. Sbar, S. Quinn, T. Wang, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1
Authors: M. Kfoury, A.-L. Voisin, M. Najean, S. Champiat, S. Laghouati, J.-M. Michot, C. Robert, C. Mateus, L. Albiges, B. Besse, C. Massard, M. Texier, O. Lambotte, A. Marabelle
Journal: Annals of Oncology (2018)
TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)
Authors: J.S. de Bono, C. Higano, F. Saad, K. Miller, M. Casey, A. Czibere, C. Healy, K. Fizazi
Journal: Annals of Oncology (2018)
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Authors: E. Martinez Moreno, A. Irigoyen Medina, R. Alvarez Cabellos, K.A. Martinez, J. Santiago, M. Rivilla, J.D. Cardenas, C. Esteban, B. Trujillo, A. Rosero, L. Fernandez, I. Ramos, A. Ramos, J.I. Chacon
Journal: Journal of Thoracic Oncology (2018)
OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer
Authors: S. Blagden, G. Bertelli, E. Frangou, C. Butcher, S. Love, M. Mackean, R.M. Glasspool, A. Cook, S. Nicum, R. Lord, M. Ferguson, R.L. Roux, M. Martinez, S. Black, A. James, H. Palmer, S. Hughes, C. Marriott, L. Howells
Journal: Annals of Oncology (2018)
Interim quality of life results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC)
Authors: Z. Maravic, L. Wyrwicz, B. Karczmarek-Borowska, A. Horvath, A. Ruiz Casado, A. Carrato Mena, N. Muszbek, P. Rakonczai
Journal: Annals of Oncology (2018)
P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Y. He, R. Guo, Y. Liu, F. Xu, Y. Wang, J. Cao, Q. Wu, Z. Han, J. Ye, L. Zhang, X. Mao, Z. Zhang, J. Liu, Y. Zhang
Journal: Journal of Thoracic Oncology (2018)
P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)
Authors: L. Yong, S. Kuo, P. Yang, P. Huang, M. Lin, K. Chen, J. Lee
Journal: Journal of Thoracic Oncology (2018)
P2.06-42 AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.
Authors: F. Zito Marino, M. Accardo, G. Poziello, A. Ronchi, V. Ciaramella, G. Vicidomini, M. Santini, F. Morgillo, R. Franco
Journal: Journal of Thoracic Oncology (2018)
Frozen Sections in Gastric Cancer
Authors: Teviah E. Sachs, Jennifer F. Tseng
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P2.16-44 Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer
Authors: H. Wada, T. Toyoda, T. Kaiho, K. Ohashi, Y. Shina, Y. Sata, A. Hata, T. Yamamoto, J. Morimoto, Y. Sakairi, H. Suzuki, T. Nakajima, I. Yoshino
Journal: Journal of Thoracic Oncology (2018)
Abstract 16783: Matrix Metalloproteinase-9 Deletion Alters the Age-Associated Inflammation Profile by Upregulating M2 Macrophage Polarization
Authors: Yonggang Ma, Ying A Chiao, Omid Ghasemi, Merry L Lindsey, Yufang Jin
Journal: Circulation (2013)

In the setting of myocardial infarction, matrix metalloproteinase-9 (MMP-9) deletion reduces macrophage infiltration into the left ventricle (LV) and attenuates LV remodeling. We recently showed th...
OA11.06 Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma
Authors: M.J. Lee, N. Kuehne, K. Hueniken, D. Shepshelovich, S. Soldera, S. Shakik, D. Patel, D. Cheng, Z. Chen, L. Eng, M.C. Brown, A. Bezjak, S. Keshavjee, D. Reisman, W. Xu, G. Liu
Journal: Journal of Thoracic Oncology (2018)
P2.01-09 Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing
Authors: E. Arriola, S. Clave, M. Hardy-Werbin, A. Taus, P. Rocha, I. Chaib, E. Carcereny, M. Salido, A. Dalmases, B. Bellosillo
Journal: Journal of Thoracic Oncology (2018)
P1.04-27 Safety of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) in the Real-Life Setting: A Single-Institution Experience from Argentina
Authors: M. Bluthgen, M. Tamburelli, C. Calderon, J. Castillo, C. Bas, G. Gomez Abuin, S. Sena
Journal: Journal of Thoracic Oncology (2018)
Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16
Authors: Pere Godoy, Arantxa Romero, Núria Soldevila, Nuria Torner, Mireia Jané, Ana Martínez, Joan A Caylà, Cristina Rius, Angela Domínguez
Journal: Eurosurveillance (2018)

Introduction When influenza vaccination is ineffective in preventing influenza virus infection, it may still reduce the severity of influenza-associated disease. Here, we estimate the effect of influenza vaccination in preventing severe outcomes e.g. intensive care unit (ICU) admission and death, even though it did not prevent influenza virus infection and subsequent hospitalisation. Methods An observational case–case epidemiological study was carried out in 12 sentinel hospitals in Catalonia (Spain) over six influenza seasons 2010/11–2015/16. Cases were individuals with severe laboratory-confirmed influenza virus infection and aged 18 years and older. For each reported case we collected demographic, virological and clinical characteristics. Logistic regression was used to estimate the crude, adjusted odd ratios (aOR) and 95% confidence intervals (CI). Results Of 1,727 hospitalised patients included in the study, 799 were female (46.7%), 591 (34.2%) were admitted to the ICU and 223 (12.9%) died. Influenza vaccination uptake was lower in cases that required ICU admission or died (21.2% vs 29.7%, p &lt; 0.001). The adjusted influenza vaccination effectiveness in preventing ICU admission or death was 23% (95% CI: 1 to 40). In an analysis restricted to sex, age group and antiviral treatment, influenza vaccination had a positive effect on disease severity in all age groups and categories. Conclusions We found that influenza vaccination reduced the severity of disease even in cases where it did not prevent infection and influenza-associated hospitalisation. Therefore, increased vaccination uptake may reduce complications, ICU admission and death.
P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
Authors: M. Bassanelli, D. Giannarelli, B. Ricciuti, V. Magri, F.L. Cecere, M. Roberto, S. Giacinti, V. Barucca, R. Cassese, A. De Giglio, S. Scagnoli, M. Milella, M. Santarelli, C. Bengala, E.M. Ruggeri, P. Marchetti, F. Cognetti, A. Gelibter, E. Cortesi, R. Chiari, A. Ceribelli
Journal: Journal of Thoracic Oncology (2018)
P3.01-61 EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer
Authors: H. Linardou, V. Kotoula, G. Kouvatseas, V. Karavasilis, G. Mountzios, E. Samantas, A. Kalogera-Fountzila, D. Televantou, K. Papadopoulou, X. Mavropoulou, E. Daskalaki, T. Zaramboukas, I. Efstratiou, S. Lambaki, G. Rallis, E. Res, K. Syrigos, P. Kosmidis, D. Pectasides, G. Fountzilas
Journal: Journal of Thoracic Oncology (2018)
Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
Authors: Y. Emi, T. Yamanaka, K. Muro, H. Uetake, E. Oki, T. Takahashi, Y. Katayose, K. Yoshida, M. Sakamoto, S. Aishima, K. Ishida, J. Imura, M. Unno, I. Hyodo, N. Tomita, K. Sugihara, Y. Maehara
Journal: Annals of Oncology (2018)
Mitochondrial transplantation in humans: “magical” cure or cause for concern?
Authors: Edoardo Bertero, Christoph Maack, Brian O’Rourke
Journal: Journal of Clinical Investigation (2018)

Mitochondrial transplantation is a therapeutic approach developed by McCully and colleagues that entails the injection of healthy mitochondria harvested from unaffected tissue into an ischemic organ of the same subject (1).It has recently been applied to human pediatric patients with myocardial ischemia (2), receiving widespread media attention accompanied by sensationalistic claims on its mechanism of action, e.g.: (a) after injection into the heart, "mitochondria moved like magnets to the proper places in the cells and began supplying energy;" and (b) after infusion into the coronary arteries, "somehow the organelles will gravitate almost magically to the injured cells that need them and take up residence" (3).According to the purported mechanism of action, the mitochondria must, seemingly, perform three "magic tricks."First, the mitochondria must survive transfer from an intracellular environment to an extracellular one with high Ca 2+ concentrations.Second, if they survive, mitochondria must produce ATP that is able to enter cardiac myocytes to support contraction.Third, enough mitochondria must pass through the cell membrane to contribute to ATP production by the host cell.A corollary to trick number three is a variation in which the mitochondria are injected into the bloodstream and somehow pass through the endothelial vascular permeability barrier, migrate into the interstitium, and are incorporated into the dysfunctional target tissue.Given the rapid translation of this method to the clinic, it behooves us to determine whether these extraordinary claims are convincingly supported.
P2.01-28 Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 – 2014 Diagnoses
Authors: A. Elegbede, H. Li, A. D'Silva, A. Gibson, R. Tudor, M. Dean, S. Otsuka, G. Bebb
Journal: Journal of Thoracic Oncology (2018)
OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
Authors: J. Brahmer, M. Schenker, K.H. Lee, M. Provencio, M. Nishio, K. Lesniewski-Kmak, R. Sangha, S. Ahmed, J. Raimbourg, K. Feeney, R. Corre, F. Franke, E. Richardet, J. Penrod, Y. Yuan, F. Nathan, P. Bhagavatheeswaran, M. De Rosa, F. Taylor, R. Lawrance, M. Reck
Journal: Journal of Thoracic Oncology (2018)
P1.16-28 The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy
Authors: G. Yavas, C. Yavas, E. Celik, E. Sen, O. Ata, D. Yuce, R. Elsurer-Afsar
Journal: Journal of Thoracic Oncology (2018)
Prognostic impact of MSI and 18qLOH in stage II colon cancer: A prospective biomarker study in the SACURA trial
Authors: T. Ishikawa, M. Ishiguro, E. Nakatani, H. Ueno, H. Uetake, K. Murotani, S. Matsui, N. Tomita, Y. Shimada, K. Takahashi, K. Kotake, M. Watanabe, H. Mochizuki, S. Teramukai, K. Sugihara
Journal: Annals of Oncology (2018)
P1.11-15 Application of Lung-RADS vs. PAN-CAN Nodule Risk Calculation in the Alberta Lung Cancer Screening Study
Authors: A. Tremblay, N. Taghizadeh, J. Macgregor, G. Armstrong, M. Bristow, T. Elliot, L. Guo, A. Lee, C. Lydell, R. Pereira, P. Maceachern, A. Graham, J. Dickinson, S. Lam, H. Yang, E. Bedard, M. Tammemagi, P. Burrowes
Journal: Journal of Thoracic Oncology (2018)
A prospective randomized controlled trial of metoclopramide combined with triple antiemetic therapy to prevent anthracycline-based chemotherapy-induced nausea and vomiting in patients with breast cancer
Authors: U. Oflazoglu, U. Varol, A. Alacacioglu, T. Salman, Y. Kucukzeybek, H. Taskaynatan, Y. Yildiz, G. Dissiz, S. Iriz, M.O. Tarhan
Journal: Annals of Oncology (2018)
Abstract 19094: Use of ACE Inhibitors or Angiotensin Receptor Blockers is Associated With a Significantly Lower Risk of 30-day All-cause and Heart Failure Readmissions and All-cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure Developing Acute Kidney Injury
Authors: Mohammed Siddiqui, Paul W Sanders, Garima Arora, Charity Morgan, Sijian Zhang, Sumanth D Prabhu, Anupam Agarwal, Gary Cutter, Ravindra L Mehta, Prakash Deedwania, Ross D Fletcher, Gregg C Fonarow, Javed Butler, Wilbert S Aronow, Wen-Chih Wu, Stefan D Anker, Richard M Allman, Ali Ahmed
Journal: Circulation (2015)

Background: We presented data that demonstrating that acute kidney injury (AKI) as defined by a rise in admission serum creatinine by ≥0.3mg/dL is associated with a 16% significant increase in 30-day all-cause readmission in hospitalized heart failure (HF) patients (Circulation. 2014; 130: A19999). We have previously published data suggesting that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) is associated with improved outcomes in HF patients with chronic kidney disease (PMC3324926 and PMC3575519). However, these drugs are often avoided in HF patients with AKI. Methods: Of the 8049 Medicare beneficiaries hospitalized for HF and discharged alive from 106 U.S. hospitals (1998-2001), 6854 had data on admission, discharge, and highest serum creatinine, of which 2180 had AKI (a rise in admission serum creatinine by ≥0.3 mg/dL) and of these 1171 (54%) received a discharge prescription for ACEIs or ARBs. Using propensity scores for ACEI or ARB use, we assembled a matched cohort of 755 pairs of patients balanced on 33 baseline characteristics including baseline serum creatinine and rise of serum creatinine. Results: 30-day all-cause readmission occurred in 21% and 27% of matched patients receiving and not receiving ACEIs or ARBs, respectively (HR, 0.77; 95% CI, 0.62-0.95; p=0.015). 30-day HF readmission occurred in 6% and 11% of matched patients receiving and not receiving ACEIs or ARBs, respectively (HR, 0.53; 95% CI, 0.37-0.76; p=0.001). 30-day all-cause mortality occurred in 5% and 9% of matched patients receiving and not receiving ACEIs or ARBs, respectively (HR, 0.89; 95% CI, 0.79-1.00; p=0.052). Both readmission and mortality benefits persisted for 12 months post-discharge (Figure). Conclusions: Among patients hospitalized for HF who developed AKI after hospital admission, discharge prescription of ACEIs or ARBs was associated with significant short- and long-term improvements in outcomes.
Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between ocreotide in combination with everolimus compared to sunitinib
Authors: A.F. Cardona Zorrilla, A. Ruiz-Patiño, O. Arrieta, L. Zatarain-Barron, F. Hakim, E. Jimenez, J.A. Mejia, F. Ramon, N. Useche, S. Bermudez, D. Pineda, H. Cifuentes, L.L. Rojas, L.E. Pino Villareal, C. Balana
Journal: Annals of Oncology (2018)
P2.16-35 Analysis of Pre and Intra Operative Factors Related to the Operation Time of Lobectomy in VATS: Is the Shape of Thoracic Cavity a Predictive Factor?
Authors: T. Nagashima, H. Ito, H. Yagasaki, K. Inafuku, J. Osawa, J. Samejima, N. Haruhiko
Journal: Journal of Thoracic Oncology (2018)
P2.06-21 Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma
Authors: V. Laszlo, T. Klikovits, A. Tisza, M. Bonta, M. Hoda, W. Berger, M. Grusch, W. Klepetko, B. Hegedus, A. Limbeck, B. Dome
Journal: Journal of Thoracic Oncology (2018)
Negative Pressure Wound Therapy for Open Fractures
Authors: Dino Papes
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of a highly suppressive Treg subset associated to immunotherapy response
Authors: E.F. Giunta, S. Romano, P. D'Arrigo, A. Rea, M. Tufano, G. Matarese, C. Procaccini, N. Novizio, V. Vigorito, D. Faicchia, G. Argenziano, V. De Falco, F. Ciardiello, M.F. Romano, T. Troiani
Journal: Annals of Oncology (2018)
Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)
Authors: A. Vozy, A. Simonaggio, E. Auclin, L. Mezquita, C. Baldini, P. Martin-Romano, B. Pistilli, A. Gazzah, R. Bahleda, V. Ribrag, S. Postel-Vinay, S. Champiat, J.-C. Soria, F. André, C. Massard, B. Besse, S. Delaloge, A. Varga
Journal: Annals of Oncology (2018)
Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss
Authors: Tomas G. Neilan, Melissa C. Price, Danita Y. Sanborn, Justin F. Gainor, Athena Chen
Journal: New England Journal of Medicine (2018)

A 57-year-old man with a history of tobacco smoking presented with confusion, cough, fever, and unintentional weight loss. An evaluation revealed consolidation in the left lower lobe and emboli to the brain, heart, spleen, kidney, and lungs. A diagnostic test was performed.
United in fight against prostate cancer registry (UFO): First results from a large, multi-center, prospective, longitudinal cohort study in Asia
Authors: H. Uemura, D. Ye, R. Kanesvaran, H. Zeng, Y.-S. Pu, E. Chiong, B. Lojanapiwat, S.K. Rawal, B.H. Chung, A.H.A. Razack, Y.-S. Tsai, Y. Liu, M. Asinas-Tan, W. Liu, G.K.M. Low, M.A.G. van Kooten Losio
Journal: Annals of Oncology (2018)
P3.04-01 Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC
Authors: A. Amann, G. Gamerith, A. Bader, W. Hahn, C. Tschida, T. Cope, A. Audetat, H. Mellert, G. Pestano, H. Zwierzina
Journal: Journal of Thoracic Oncology (2018)
P2.06-08 ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo
Authors: P.L. Chia, D. Cao, H. Gan, A. Rigopoulos, E. Riley, A. Phillips, T. John, A. Scott
Journal: Journal of Thoracic Oncology (2018)
Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma
Authors: S. Secondino, P. Bossi, A. Gurrado, S. Basso, I. Imarisio, A. Pagani, M. Zecca, I. Pisani, J. Bagnarino, M. Casanova, C. Bergamini, C. Perotti, L.F. Licitra, P. Comoli, P. Pedrazzoli
Journal: Annals of Oncology (2018)